Humanization of recombinant antibodies

Recombinant Antibodies for Immunotherapy

Volumn , Issue , 2009, Pages 3-19

  Saldanha, José W ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880111000     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596773.004     Document Type: Chapter

References (74)

1. Al-Lazikani B, Lesk AM, Chothia C. (1997) Standard conformations for the canonical structure of immunoglobulins. J. Mol. Biol. 273, 927-48.
2. Baca M, Presta LG, O'Connor SJ, Wells JA. (1997) Antibody humanization using monovalent phage display. J. Biol. Chem. 272, 10678-84.
3. Boulianne GL, Hozumi N, Shulman MJ. (1984) Production of functional chimaeric mouse/human antibody. Nature. 312, 643-6.
4. Bourne PC, Terzyan SS, Cloud G, Landolfi NF, Vasquez M, Edmundson AB. (2004) Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms. Acta Crystallogr. D. Biol Crystallogr. 60, 1761-9.
5. Brüggemann M, Spicer C, Buluwela L, Rosewell I, Barton S, Surani MA, Rabbitts TH. (1991) Human antibody production in transgenic mice: expression from 100kb of the human IgH locus. Eur. J. Immunol. 21, 1323-6.
6. Brüggemann M, Winter G, Waldmann H, Neuberger MS. (1989) The immunogenicity of chimeric antibodies. J. Exp. Med. 170, 2153-7.
7. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ. (1989) Conformations of immunoglobulin hypervariable regions. Nature 342, 877-83.
8. Chothia C, Lesk AM. (1987) Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-17.
9. Chothia C, Novotny J, Bruccoleri R, Karplus M. (1985) Domain association in immunoglobulin molecules. The packing of variable domains. J. Mol. Biol. 186, 651-63.
10. Co MS, Deschamps M, Whitley RJ, Queen C. (1991) Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. U.S.A. 88, 2869-73.
11. Co MS, Scheinberg DA, Avdalovic NM, McGraw K, Vasquez M, Caron PC, Queen C. (1993) Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol. Immunol. 30, 1361-7.
12. Dall'Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H. (2005) Antibody humanization by framework shuffling. Methods 36, 43-60.
13. Damschroder MM, Widjaja L, Gill PS, Krasnoperov V, Jiang W, Dall'Acqua WF, Wu H. (2007) Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol. Immunol. 44, 3049-60.
14. Daugherty BL, DeMartino JA, Law MF, Kawka DW, Singer II, Mark GE. (1991) Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 19, 2471-6.
15. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155, 925-37.
16. Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, Roodt J, Desmet J, Deckmyn H. (2006) Rational humanization of the powerful antithrombotic anti-GPIba antibody: 6B4. Thromb. Haemost. 96, 671-84.
17. Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV. (2004) SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol. Immunol. 41, 863-72.
18. Gorman SD, Clark MR, Routledge EG, Cobbold SP, Waldmann H. (1991) Reshaping a therapeutic CD4 antibody. Proc. Natl. Acad. Sci. U.S.A. 88, 4181-5.
19. Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, Coleman K, Pfefferkorn LC, Fanger MW, Guyre PM. (1995) Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J. Immunol. 155, 4996-5002.
20. Hakimi J, Ha VC, Lin P, Campbell E, Gately MK, Tsudo M, Payne PW, Waldmann TA, Grant AJ, Tsien WH, Schneider WP. (1993) Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC. J. Immunol. 151, 1075-85.
21. Hamilton AA, Manuel DM, Grundy JE, Turner AJ, King SI, Adair JR, White P, Carr FJ, Harris WJ. (1997) A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. J. Infect. Dis. 176, 59-68.
22. Hellendoorn K, Jones T, Watkins J, Baker M, Hamilton A, Carr F. (2004) Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™). Cancer Cell Intl. 4, S20.
23. Hwang WY, Foote J. (2005) Immunogenicity of engineered antibodies. Methods 36, 3-10.
24. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. (1986) Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41, 572-8.
25. Jensen M, Klehr M, Bogel A, Schmitz S, Tawadros S, Mühlenhoff M, Plück A, Fischer T, Schomäcker K, Schultze, JL, Berthold F. (2007) One step generation of fully chimeric antibodies using Cc1- and Cj mutant mice. J. Immunother. 30, 338-49.
26. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. (1994) Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology 12, 899-903.
27. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. (1986) Replacing the complementaritydetermining regions in a human antibody with those from a mouse. Nature 321, 522-5.
28. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, SchneiderWP, Queen C. (1990) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy inmalignant and immune disorders. Cancer Res. 50, 1495-502.
29. Kabat EA, Wu TT, Perry H, Gottesman K, Foeller C. (1991) Sequences of Proteins of Immunological Interest, 5th ed. NIH Publication No. 91-3242.
30. Kabat EA, Wu TT, Reid-MillerM, Perry H, Gottesman K. (1987) Sequences of Proteins of Immunological Interest, 4th ed. US Govt. Printing Office No. 165-492.
31. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4, 773-83.
32. Köhler G, Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-7.
33. Kolbinger F, Saldanha J, Hardman N, Bendig MM. (1993) Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng. 6, 971-80.
34. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. (2007) A molecular immunology approach to antibody humanization and functional optimization. Mol. Immunol. 44, 1986-1998.
35. Léger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM. (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies 8, 3-16.
36. Li J, Sai T, Berger M, Chao Q, Davidson D, et al. (2006) Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc. Natl. Acad. Sci. U.S.A. 103, 3557-62.
37. Lv M, Li Y, Yu M, Sun Y, Lin Z, Qiao C, Luo Q, Gu X, Huang Y, Feng J, Shen B. (2007) Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design. Int. J. Biochem. Cell Biol. 39, 1142-55.
38. Maeda H, Matsushita S, Eda Y, Kimachi K, Tokiyoshi S, Bendig MM. (1991) Construction of reshaped human antibodies with HIV-neutralizing activity. Hum. Antibodies Hybridomas. 2, 124-34.
39. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-4.
40. Morelock MM, Rothlein R, Bright SM, Robinson MK, Graham ET, Sabo JP, Owens R, King DJ, Norris SH, Scher DS, et al. (1994) Isotype choice for chimeric antibodies affects binding properties. J. Biol. Chem. 269, 13048-55.
41. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 81, 6851-5.
42. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N. (2000) Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol. Immunol. 37, 1035-46.
43. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH. (1985) A haptenspecific chimaeric IgE antibody with human physiological effector function. Nature 314, 268-70.
44. Nisihara T, Ushio Y, Higuchi H, Kayagaki N, Yamaguchi N, Soejima K, Matsuo S, Maeda H, Eda Y, Okumura K, Yagita H. (2001) Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction. J. Immunol. 167, 3266-75.
45. Ohlin M, Owman H, Mach M, Borrebaeck CA. (1996) Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol. Immunol. 33, 47-56.
46. Padlan EA, Abergel C, Tipper JP. (1995) Identification of specificity-determining residues in antibodies. FASEB J. 9, 133-9.
47. Padlan EA. (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28, 489-98.
48. Padlan EA. (1994) Anatomy of the antibody molecule. Mol. Immunol. 31, 169-217.
49. Pedersen JT, Henry AH, Searle SJ, Guild BC, Roguska M, Rees AR. (1994) Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J. Mol. Biol. 235, 959-73.
50. Poul MA, Ticchioni M, Bernard A, Lefranc MP. (1995) Inhibition of T cell activation with a humanized anti-beta 1 integrin chain mAb. Mol. Immunol. 32, 101-16.
51. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. U.S.A. 86, 10029-33.
52. Rader C, Cheresh DA, Barbas CF 3rd. (1998) A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc. Natl. Acad. Sci. U.S.A. 95, 8910-5.
53. Riechmann L, Clark M, Waldmann H, Winter G. (1988) Reshaping human antibodies for therapy. Nature 332, 323-7.
54. Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P. (1992) Engineering a humanized bispecific F(ab#)2 fragment for improved binding to T cells. Int J Cancer Suppl. 7, 45-50.
55. Rosok MJ, Yelton DE, Harris LJ, Bajorath J, Hellstrom KE, Hellstrom I, Cruz GA, Kristensson K, Lin H, Huse WD, Glaser SM. (1996) A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J. Biol. Chem. 271, 22611-8.
56. Saldanha JW, Martin AC, Léger OJ. (1999) A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells. Mol. Immunol. 36, 709-19.
57. Sato K, Ohtomo T, Hirata Y, Saito H, Matsuura T, Akimoto T, Akamatsu K, Koishihara Y, Ohsugi Y, Tsuchiya M. (1996) Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region. Hum. Antibodies. Hybridomas 7, 175-83.
58. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851-6.
59. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. (1994) Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol. Immunol. 31, 371-81.
60. Schneider WP, Glaser SM, Kondas JA, Hakimi J. (1993) The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3. J. Immunol. 150, 3086-90.
61. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr. (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45, 879-85.
62. Shearman CW, Pollock D, White G, Hehir K, Moore GP, Kanzy EJ, Kurrle R. (1991) Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor. J. Immunol. 147, 4366-73.
63. Shirai H, Kidera A, Nakamura H. (1996) Structural classification of CDR-H3 in antibodies. FEBS Lett. 399, 1-8.
64. Shirai H, Kidera A, Nakamura H. (1999) H3-rules: identification of CDR-H3 structures in antibodies. FEBS Lett. 455, 188-97.
65. Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, Van Rompaey I, Stassen JM, Deckmyn H, Vanhoorelbeke K. (2006) Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modeling of variable domains. Mol. Immunol. 43, 1243-57.
66. Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. (2002) "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169, 1119-25.
67. Tempest PR, White P, Buttle M, Carr FJ, Harris WJ. (1995) Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. Int. J. Biol. Macromol. 17, 37-42.
68. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389-401.
69. Vargas-Madrazo E, Paz-García E. (2003) An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues. J. Mol. Recognit. 16, 113-20.
70. Verhoeyen M, Milstein C, Winter G. (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239, 1534-6.
71. Wu H, Nie Y, Huse WD, Watkins JD. (1999) Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294, 151-62.
72. Wu TT, Kabat EA. (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 132, 211-50.
73. Yoon SO, Lee TS, Kim SJ, Jang MH, Kang YJ, Park JH, Kim KS, Lee HS, Ryu CJ, Gonzales NR, Kasmiri SV, Lim SM, Choi CW, Hong HJ. (2006) Construction, affinity maturation and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 281, 6985-92.
74. Zhang W, Feng J, Li Y, Guo N, Shen B. (2005) Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling. Mol. Immunol. 42, 1445-51.